MX2024000965A - Medicamento para el tratamiento y/o prevencion de cancer. - Google Patents

Medicamento para el tratamiento y/o prevencion de cancer.

Info

Publication number
MX2024000965A
MX2024000965A MX2024000965A MX2024000965A MX2024000965A MX 2024000965 A MX2024000965 A MX 2024000965A MX 2024000965 A MX2024000965 A MX 2024000965A MX 2024000965 A MX2024000965 A MX 2024000965A MX 2024000965 A MX2024000965 A MX 2024000965A
Authority
MX
Mexico
Prior art keywords
medicament
cancer
prevention
treatment
antibody
Prior art date
Application number
MX2024000965A
Other languages
English (en)
Inventor
Fumiyoshi Okano
Takanori Saito
Ukei WASAI
Masahiko Kume
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of MX2024000965A publication Critical patent/MX2024000965A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a un medicamento para el tratamiento y/o prevención del cáncer, que comprende un anticuerpo o un fragmento del mismo que tiene reactividad inmunológica con la proteína CAPRIN-1 y un inhibidor de la vía MAPK juntos o por separado en combinación.
MX2024000965A 2021-07-27 2022-07-27 Medicamento para el tratamiento y/o prevencion de cancer. MX2024000965A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021122072 2021-07-27
PCT/JP2022/028878 WO2023008462A1 (ja) 2021-07-27 2022-07-27 癌の治療及び／又は予防のための医薬品

Publications (1)

Publication Number Publication Date
MX2024000965A true MX2024000965A (es) 2024-02-09

Family

ID=85087690

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024000965A MX2024000965A (es) 2021-07-27 2022-07-27 Medicamento para el tratamiento y/o prevencion de cancer.

Country Status (8)

Country Link
EP (1) EP4378478A1 (es)
JP (1) JPWO2023008462A1 (es)
KR (1) KR20240041917A (es)
CN (1) CN117677398A (es)
AU (1) AU2022320304A1 (es)
CA (1) CA3227706A1 (es)
MX (1) MX2024000965A (es)
WO (1) WO2023008462A1 (es)

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0770628B9 (en) 1994-07-13 2007-02-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
IL138801A0 (en) 1998-04-03 2001-10-31 Chugai Pharmaceutical Co Ltd Humanized antibody against human tissue factor and process for the preparation thereof
PT2180007E (pt) 1998-04-20 2013-11-25 Roche Glycart Ag Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2270147B2 (en) 1999-04-09 2020-07-22 Kyowa Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
EP1587540B1 (en) 2003-01-09 2021-09-15 MacroGenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
DE10359795A1 (de) 2003-12-19 2005-07-21 Bayer Technology Services Gmbh Strangverdampfervorrichtung
PL2322221T3 (pl) 2008-08-05 2015-01-30 Toray Industries Kompozycja farmaceutyczna do leczenia i zapobiegania raka
CA2766405A1 (en) 2009-06-22 2011-01-13 Medimmune, Llc Engineered fc regions for site-specific conjugation
KR101545914B1 (ko) 2009-09-22 2015-08-20 프로바이오겐 아게 특수화된 글리칸 구조를 함유하는 분자의 생산 방법
AU2010343102B2 (en) 2009-12-29 2016-03-24 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
PT2532743E (pt) 2010-02-04 2015-08-04 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção de cancro
EP2532364B1 (en) 2010-02-04 2016-05-04 Toray Industries, Inc. Pharmaceutical composition comprising anti caprin-1 antibodies for treating and/or preventing cancer
AU2011211684B2 (en) 2010-02-04 2014-09-25 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
WO2011096533A1 (ja) 2010-02-04 2011-08-11 東レ株式会社 癌の治療及び／又は予防用医薬組成物
CA2788715C (en) 2010-02-04 2021-06-08 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
CN109925511B (zh) 2010-02-04 2024-03-19 东丽株式会社 用于癌的治疗和/或预防的药物
WO2011103196A1 (en) 2010-02-17 2011-08-25 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
CA2794708C (en) 2010-03-29 2021-11-16 Zymeworks Inc. Antibodies with enhanced or suppressed effector function
HUE030130T2 (en) 2011-08-04 2017-04-28 Toray Industries A pharmaceutical composition for the treatment and / or prevention of pancreatic cancer
JP6070191B2 (ja) 2011-08-04 2017-02-01 東レ株式会社 癌の治療及び／又は予防用医薬組成物
PL2740793T3 (pl) 2011-08-04 2018-04-30 Toray Industries, Inc. Kompozycja leku do leczenia i/lub zapobiegania nowotworowi
CA2844034C (en) 2011-08-04 2019-07-16 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
JP6065592B2 (ja) 2011-08-04 2017-01-25 東レ株式会社 癌の治療及び／又は予防用医薬組成物
TR201808595T4 (tr) 2011-08-04 2018-07-23 Toray Industries Kanser hastalıklarının tedavisi ve/veya profilaksisi için farmasötik bileşim.
WO2013086260A2 (en) * 2011-12-09 2013-06-13 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of cancer
KR102009236B1 (ko) 2012-02-21 2019-08-09 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
ES2749672T3 (es) 2012-02-21 2020-03-23 Toray Industries Composición farmacéutica para tratar y/o prevenir el cáncer
JP6187255B2 (ja) 2012-02-21 2017-08-30 東レ株式会社 癌の治療及び／又は予防用医薬組成物
HUE034736T2 (en) 2012-02-21 2018-02-28 Toray Industries A pharmaceutical composition for the treatment and / or prevention of cancer
CA2869123C (en) 2012-03-30 2021-03-16 Toray Industries, Inc. Pharmaceutical composition comprising anti-caprin-1 antibodies for the treatment of gallbladder cancer
RU2640245C2 (ru) 2012-03-30 2017-12-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или предотвращения рака печени
CN103566377A (zh) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
PL3031826T3 (pl) 2013-08-09 2019-03-29 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi
KR20160076519A (ko) 2013-10-10 2016-06-30 아락세스 파마 엘엘씨 Kras g12c 억제제
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
EA038028B1 (ru) 2015-11-09 2021-06-24 Астразенека Аб Производные дигидроимидазопиразинона, применимые в лечении рака
EP3377481A1 (en) 2015-11-16 2018-09-26 Araxes Pharma LLC 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
EP3458445B1 (en) 2016-05-18 2021-02-17 Mirati Therapeutics, Inc. Kras g12c inhibitors
JOP20190186A1 (ar) 2017-02-02 2019-08-01 Astellas Pharma Inc مركب كينازولين
WO2019099524A1 (en) 2017-11-15 2019-05-23 Mirati Therapeutics, Inc. Kras g12c inhibitors
CN111542529B (zh) 2017-11-30 2023-06-30 韩美药品株式会社 对蛋白激酶具有抑制活性的噻吩并[3,2-d]嘧啶化合物
US10597405B2 (en) 2017-12-08 2020-03-24 Astrazeneca Ab Chemical compounds
CN111406448B (zh) 2017-12-19 2021-12-14 株式会社富士 安装装置、检测装置及检测方法
US10829487B2 (en) 2017-12-21 2020-11-10 Boehringer Ingelheim International Gmbh Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors
MX2020009862A (es) * 2018-03-30 2020-10-08 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
JP2022517222A (ja) 2019-01-10 2022-03-07 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｃ阻害剤
AU2020279287A1 (en) 2019-05-21 2021-12-16 InventisBio Co., Ltd. Heterocyclic compounds, preparation methods and uses thereof
TW202110848A (zh) 2019-05-24 2021-03-16 大陸商江蘇恆瑞醫藥股份有限公司 取代的稠合雙環類衍生物、其製備方法及其在醫藥上的應用
EP3763711A1 (en) 2019-07-09 2021-01-13 Allinky Biopharma Tetrahydroisoquinoline compounds
CN112574207B (zh) 2019-09-30 2023-04-11 南京药石科技股份有限公司 Erk1/2蛋白激酶抑制剂及其用途
CN112694475A (zh) 2019-10-23 2021-04-23 苏州泽璟生物制药股份有限公司 环烷基类和杂环烷基类抑制剂及其制备方法和应用
WO2021108683A1 (en) 2019-11-27 2021-06-03 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
MX2022006663A (es) 2019-12-02 2022-07-05 Shanghai Yingli Pharm Co Ltd Compuesto heterociclico que contiene oxigeno, metodo de preparacion de este y uso de este.
CA3160899C (en) 2019-12-06 2024-04-16 Medshine Discovery Inc. Spiro compound serving as erk inhibitor, and application thereof
WO2021110141A1 (zh) 2019-12-06 2021-06-10 南京明德新药研发有限公司 Pan-RAF激酶抑制剂的联芳基化合物
CN112920183B (zh) 2019-12-06 2024-07-19 南京圣和药业股份有限公司 作为kras-g12c抑制剂的化合物及其应用
WO2021113595A1 (en) 2019-12-06 2021-06-10 Beta Pharma, Inc. Phosphorus derivatives as kras inhibitors
CA3162883A1 (en) 2019-12-10 2021-06-17 F. Hoffmann-La Roche Ag (3r)-and (3s)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide compounds and their use as braf inhibitors
PL3886991T3 (pl) 2019-12-11 2022-11-21 Eli Lilly And Company Inhibitory KRAS G12C
KR20220119088A (ko) 2019-12-19 2022-08-26 자코바이오 파마슈티칼스 컴퍼니 리미티드 Kras 돌연변이체 단백질 억제제
WO2021120890A1 (en) 2019-12-20 2021-06-24 Novartis Ag Pyrazolyl derivatives useful as anti-cancer agents
CN114929704B (zh) 2019-12-27 2024-07-23 微境生物医药科技(上海)有限公司 含螺环的喹唑啉化合物
CN113045565A (zh) 2019-12-27 2021-06-29 微境生物医药科技(上海)有限公司 新型K-Ras G12C抑制剂
JPWO2021182573A1 (es) * 2020-03-12 2021-09-16
WO2021203768A1 (zh) 2020-04-08 2021-10-14 江苏恒瑞医药股份有限公司 嘧啶并二环类衍生物、其制备方法及其在医药上的应用
WO2021216770A1 (en) 2020-04-22 2021-10-28 Accutar Biotechnology Inc. Substituted tetrahydroquinazoline compounds as kras inhibitors
US20230203055A1 (en) 2020-04-28 2023-06-29 Betta Pharmaceuticals Co., Ltd Fused ring compound and application thereof in medicine
CN115135636B (zh) 2020-04-29 2024-08-23 北京泰德制药股份有限公司 喹喔啉酮衍生物作为kras g12c突变蛋白的不可逆抑制剂
CN113563323B (zh) 2020-04-29 2023-12-01 上海凌达生物医药有限公司 一类苯并噻唑基联芳基类化合物、制备方法和用途
TW202144349A (zh) 2020-04-30 2021-12-01 大陸商上海科州藥物研發有限公司 作為ｋｒａｓ抑制劑的雜環化合物的製備及其應用方法
JP7296017B2 (ja) 2020-04-30 2023-06-21 メッドシャイン ディスカバリー インコーポレイテッド ベンゾスルタムを含む化合物
BR112022022761A2 (pt) 2020-05-09 2023-02-14 Chia Tai Tianqing Pharmaceutical Group Co Ltd Inibidor de sos1 contendo fósforo
TWI799871B (zh) 2020-05-27 2023-04-21 大陸商勁方醫藥科技(上海)有限公司 三環并環類化合物，其製法與醫藥上的用途
EP4161934A1 (en) 2020-06-04 2023-04-12 Antengene Discovery Limited Inhibitors of kras g12c protein and uses thereof
WO2021252339A1 (en) 2020-06-08 2021-12-16 Accutar Biotechnology, Inc. Substituted purine-2,6-dione compounds as kras inhibitors
US20230242544A1 (en) 2020-06-30 2023-08-03 InventisBio Co., Ltd. Quinazoline compounds, preparation methods and uses thereof
WO2022017339A1 (zh) 2020-07-20 2022-01-27 江苏恒瑞医药股份有限公司 稠合哒嗪类衍生物、其制备方法及其在医药上的应用
EP4186903A4 (en) 2020-07-24 2024-08-07 Medshine Discovery Inc QUINAZOLINE COMPOUND
CN116194446A (zh) 2020-08-06 2023-05-30 北京泰德制药股份有限公司 Sos1抑制剂、包含其的药物组合物及其用途
WO2022042630A1 (en) 2020-08-26 2022-03-03 InventisBio Co., Ltd. Heteroaryl compounds, preparation methods and uses thereof

Also Published As

Publication number Publication date
JPWO2023008462A1 (es) 2023-02-02
CA3227706A1 (en) 2023-02-02
WO2023008462A1 (ja) 2023-02-02
CN117677398A (zh) 2024-03-08
AU2022320304A1 (en) 2024-02-29
EP4378478A1 (en) 2024-06-05
KR20240041917A (ko) 2024-04-01

Similar Documents

Publication Publication Date Title
MX2020009862A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
CA3156451A1 (en) ANTIBODIES WITH SPECIFICITY FOR NECTIN-4 AND THEIR USES
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
MX348579B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX348581B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
MX2020008445A (es) Metodos para tratar el cancer con anticuerpos anti-pd-1.
WO2021239935A9 (en) Neutralizing antibodies against sars-related coronavirus
MX2022003005A (es) Composiciones y metodos de anticuerpos anti-cd39.
WO2022167816A3 (en) Antibodies
PH12020552222A1 (en) Immunodominant proteins and fragments in multiple sclerosis
MX2021006362A (es) Anticuerpos de dominio simple contra cll-1.
MX2022008471A (es) Anticuerpo anti-angptl3 y uso del mismo.
NZ602515A (en) Proteins that bind pi16 and uses thereof
MX2023000589A (es) Terapia de combinacion para tratar el crecimiento celular anormal.
MX2024002182A (es) Proteinas de union al factor de crecimiento transformante receptor beta ii (tgf-beta-rii).
MX2023011848A (es) Tratamientos contra el prurigo nodular.
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.
MX2024000965A (es) Medicamento para el tratamiento y/o prevencion de cancer.
WO2020086479A9 (en) Dosing
AU2018244677A1 (en) Antibody binding specifically to N-terminal region of lysyl-tRNA synthetase exposed on cell membrane
BR112023023453A2 (pt) Anticorpo anti-tigit ou um fragmento de ligação ao antígeno deste e composições farmacêuticas compreendendo o referido anticorpo ou fragmento de ligação ao antígeno
MX2024001099A (es) Medicamento para el tratamiento y/o prevencion de cancer.
MX2022011591A (es) Anticuerpos anti-ceramida.
MX2022006728A (es) Metodos y combinaciones para el tratamiento del cancer utilizando anticuerpos inhibidores de puntos de control inmunitario.
WO2021058711A3 (en) Antigen binding proteins